Friday, 15 Dec 2017

You are here

Mixed Results with Combination Therapy in Gout

Lesinurad, a selective URAT-1 inhibitor has been approved for coadministration with a urate-lowering therapy (ULT) in patients with gout for nearly a year. The CRYSTAL study was one of the studies that lead to FDA approval.

CRYSTAL was a 12 month study of 324 patients with tophaceous gout assessed the efficacy of lesinurad in combination with febuxostat. Patients were required to have an elevated serum urate (sUA) ≥8.0 mg/dl (or ≥6.0 mg/dl on ULT) and a measurable target tophus; and had to be on febuxostat 80mg daily for 3 weeks before randomization to lesinurad (200 or 400mg daily) or placebo.

Primary endpoint was achieving sUA <5.0 mg/dl by month 6 and the secondary end point was complete tophus resolution.

Significantly more patients achieved sUA < 5.0 with lesinurad 400mg (76.1%; P<0.0001) compared to placebo. The lesinurad 200mg dose was not significantly different (56.6%; P=0.13), than placebo and febuxostat (46.8%).

While tophus resolution on lesinurad was numerically (nearly 50% reduction) better than placebo at 12 months, this did not achieve statistical significance.

Safety findings were similar with the exception of higher rates of reversible serum creatinine elevation with lesinurad 400mg.

These data suggest that lesinurad in combination with febuxostat demonstrated superior sUA lowering compared with febuxostat alone, with clinically relevant impact on tophi resolution. 

The limited efficacy of the 200 mg dose and renal risks with the 400 mg dose of lesinurad may limit the use of this agent in many patients with gout.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Febuxostat Works in Early Gout But Fails to Protect from Xray Damage

Dalbeth and colleagues have published a novel report in Arthritis & Rheumatology, novel in that it is a trial of early gout patients that looks at clinical and radiographic outcomes. They showed that febuxostat improves magnetic resonance imaging (MRI) measures of synovitis and reduced gout flares, but failed to alter X-ray progression with 2 years follow-up. 

Gout Associated with Work Absenteeism

Annals of Rheumatic Disease reports that gout is associated with higher work absenteeism and thus, increased costs for society due to productivity loss.

Using Swedish national and regional registry data from 2000 to 2012, researchers studied 4571 gout patients of working age, and compared them to 22 482 population controls and assessed patient characteristics, work-loss days (absenteeism), sick leave and disability.

Good News from ACR17 - Gout

The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

Ironwood Featured Presentations

Ironwood Pharmaceuticals, Inc. (IRWD) today announced one oral and twelve poster presentations to be presented at the upcoming ACR/ARHP Annual Meeting in San Diego, California from November 3-8, 2017. The meeting is hosted by the American College of Rheumatology and Association of Rheumatology Health Professionals.

Gout Increases Risk of Stroke Moreso than MI

Gout coassociates with many of the disorders within the metabolic syndrome - diabetes, hypertension, hyperlipidemia and obesity.  Not surprisingly, gout is a risk factor for cardiovascular disease, but the risk magnitude for  myocardial infarction (MI), and stroke are unclear.